IFN-Conditioned Dendritic Cells for the Therapy of Melanoma
- 1 October 2011
- journal article
- letter
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 34 (8) , 607-609
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Interferon-conditioned Dendritic Cells for Melanoma ImmunotherapyJournal of Immunotherapy, 2011
- IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activityImmunobiology, 2011
- Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaJournal of Translational Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitisScandinavian Journal of Gastroenterology, 2010
- Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnnals of Oncology, 2006
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanomaBritish Journal of Cancer, 2003
- Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28Cancer Immunology, Immunotherapy, 2002
- Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance1999